Document text
Principal Investigator: Robert Alan Baiocchi
Organization: OHIO STATE UNIVERSITY
Fiscal Year: 2024
Award: $249,809
Funding agency: National Cancer Institute
PROJECT SUMMARY
The Ohio State University Comprehensive Cancer Center (OSUCCC) is in its 44th year as an NCI-designated
comprehensive cancer center, having received an “exceptional” overall merit descriptor in its last two reviews in
2010 and 2015, and is requesting continued federal support for the next five years. The OSUCCC mission
remains to reduce cancer morbidity and mortality through basic, population, translational and clinical research.
Through thoughtful strategic planning, attention to the cancer burden in the catchment area (the state of Ohio),
effective organizational capabilities and targeted investment, the Director and his Senior Leadership team will
enable the OSUCCC to advance collaborative cancer research with local, national, and global partners on
initiatives of the highest priority to the OSUCCC. The 293 full and introductory members are currently served by
16 full and two developing shared resources and are distributed among our five Research Programs: Cancer
Biology (formerly Molecular Biology and Cancer Genetics), Cancer Control, Leukemia Research, Molecular
Carcinogenesis and Chemoprevention and Translational Therapeutics. The OSUCCC fosters collaborative basic
research and implements strategies that advance and translate early discovery into clinical and population-based
research and addresses the needs of our catchment area through research, engagement, and outreach, from
etiology through prevention, treatment and survivorship regarding the major cancers afflicting our catchment
area population. The OSUCCC trains the next generation of cancer-focused scientists and clinicians through
new and established programs focused on integrating training for collaborative research efforts. Under the
leadership of a new Director, Raphael Pollock, MD, PhD, The OSUCCC supports innovative research efforts
within four strategic planning priorities: immuno-oncology, cancer engineering, translational genomics and
cancer prevention and survivorship. Since the last CCSG competitive renewal, the OSUCCC has shown
significant growth demonstrated by: 1) the recruitment of 108 basic, population, and translational science faculty
who are OSUCCC members; 2) the addition of 94,647 ft2 research and administrative space under the full control
of the OSUCCC Director; 3) a 16% increase in direct cancer-related funding to $75.4M, with $44.3M coming
from the NCI; 4) accrual of 14,996 patients to interventional clinical trials (5,648 accruals to therapeutic trials); 5)
increased collaborative and impactful research demonstrated by 3,477 peer-reviewed publications in which 74%
of manuscripts are multi-institutional and 85% are collaborative (i.e., inter-, intra-programmatic or multi-
institutional); 497 are published in journals with an impact factor >10; 6) the addition of two new shared resources
at an institutional investment of $1.3M; and 7) preclinical and clinical development of an FDA approved drug
which has changed the treatment for CLL and other blood cancers. With new recruits and strong institutional and
philanthropic support in place, the OSUCCC is building upon the momentum and poised in the next five years to
take significant steps toward achieving our mission and our broad vision of living in a cancer-free world.
Terms: <AIDS><AIDS Malignancy Consortium><AIDS Virus><AIDS associated cancer><AIDS lymphoma><AIDS related cancer><AIDS-Associated Lymphoma><AIDS-Related Diffuse Large B-cell Lymphoma><AIDS-Related Lymphoma><AIDS-Related Malignancy><AIDS-Related Malignant Neoplasm><AIDS-associated malignancies><AIDS/HIV><Accounting><Acquired Immune Deficiency><Acquired Immune Deficiency Syndrome><Acquired Immune Deficiency Syndrome Virus><Acquired Immunodeficiency Syndrome><Acquired Immunodeficiency Syndrome Virus><Address><Africa South of the Sahara><Appalachia><Appalachian><Appalachian Region><Attention><B-Cell Differentiation Factor Gene><B-Cell Stimulatory Factor 2 Gene><B7-H1><B7H1><BSF-2 Gene><BSF2 Gene><Basic Research><Basic Science><Behavior><Beta-2 Gene Interferon><Biological><Biology><Body Tissues><Bone-Derived Transforming Growth Factor><Breast><Burkitt Herpesvirus><Burkitt Lymphoma Virus><CCSG><CD274><CD86><CD86 gene><Cancer Biology><Cancer Burden><Cancer Cause><Cancer Center><Cancer Center Director><Cancer Center Support Grant><Cancer Control><Cancer Control Science><Cancer Etiology><Cancer Survivorship><Cancers><Catchment Area><Causality><Cell Proliferative Activity><Cellular Proliferation Rate><Cervical Cancer><Cervix Cancer><Cessation of life><Chemoprevention><Classification><Clinical><Clinical Research><Clinical Study><Clinical Trials><Colon or Rectum><Colorectal><Combined Modality Therapy><Community Networks><Community Outreach><Comprehensive Cancer Center><Culturally Appropriate Education><Culturally Responsive Education><Culture-Based Education><DLBCL><DNA Molecular Biology><Data><Death><Descriptor><Developed Countries><Development><Diagnosis><Diffuse Large B-Cell Lymphoma><Disease><Disorder><Disparities><Disparity><Doctor of Philosophy><Drugs><EB virus><EBV><Education and Outreach><Educational Activities><Endometrial><Engineering><Epidemic><Epstein Barr Virus><Etiology><Evaluation><Event><Experimental Therapies><Extranodal><FDA approved><Faculty><Flow Cytofluorometries><Flow Cytofluorometry><Flow Cytometry><Flow Microfluorimetry><Flow Microfluorometry><Fostering><Funding><General Population><General Prognostic Factor><General Public><Generalized Growth><Germinoblastic Sarcoma><Germinoblastoma><Growth><HHV-4><HHV4><HIV><HIV Associated Lymphoma><HIV Infections><HIV Lymphoma><HIV-Associated Cancer><HIV-Related Lymphoma><HIV-associated malignancy><HIV-related malignancy><HIV/AIDS><HIV/AIDS-associated malignancy><HIV/AIDS-related cancer><HPV Vaccination><HSF Gene><HTLV-III Infections><HTLV-III-LAV Infections><Healthcare><Hematologic Cancer><Hematologic Malignancies><Hematologic Neoplasms><Hematological Malignancies><Hematological Neoplasms><Hematological Tumor><Hematopoietic Cancer><Hematopoietic Cell Tumor><Hematopoietic Malignancies><Hematopoietic Neoplasms><Hematopoietic Neoplasms including Lymphomas><Hematopoietic Tumor><Hematopoietic and Lymphoid Cell Neoplasm><Hematopoietic and Lymphoid Neoplasms><Hepatocyte Stimulatory Factor Gene><Herpesviridae><Herpesviruses><Human><Human Herpesvirus 4><Human Immunodeficiency Viruses><Human Papilloma Virus Vaccination><Human Papillomavirus Vaccination><Human T-Lymphotropic Virus Type III Infections><Hybridoma Growth Factor Gene><IFNB2 Gene><IL-6 Gene><IL6><IL6 gene><Immune><Immune Diseases><Immune Disorders><Immune Dysfunction><Immune Evasion><Immune System Diseases><Immune System Disorder><Immune System Dysfunction><Immune System and Related Disorders><Immunes><Immunochemical Immunologic><Immunodeficiency and Immunosuppression Disorders><Immunologic><Immunologic Diseases><Immunological><Immunological Diseases><Immunological Dysfunction><Immunological System Dysfunction><Immunologically><Immunologics><Immunooncology><Individuals from minority><Individuals of minority><Industrialized Countries><Industrialized Nations><Infectious Mononucleosis Virus><Infiltration><Institution><Instruction and Outreach><Interleukin 6 (Interferon, Beta 2) Gene><Interleukin-6 Gene><Intervention><Intervention Strategies><Investigational Therapies><Investigational Treatments><Investments><Journals><LAV-HTLV-III><LGBTQ><LMIC><Leadership><Lesbian Gay Bi-sexual Transgender Queer><Lesbian Gay Bisexual Transgender Queer><Low-resource area><Low-resource community><Low-resource environment><Low-resource region><Low-resource setting><Lung><Lung Respiratory System><Lymphadenopathy-Associated Virus><Lymphoma><Lymphoma cell><Macrophage><Magazine><Malignant Cervical Neoplasm><Malignant Cervical Tumor><Malignant Hematologic Neoplasm><Malignant Hematopoietic Neoplasm><Malignant Lymphoma><Malignant Neoplasm of the Cervix><Malignant Neoplasms><Malignant Tumor><Malignant Tumor of the Cervix><Malignant Tumor of the Cervix Uteri><Malignant Uterine Cervix Neoplasm><Malignant Uterine Cervix Tumor><Malignant neoplasm of cervix uteri><Manuscripts><Medication><Methods><Milk Growth Factor><Minority Groups><Minority People><Minority Population><Minority individual><Mission><Mitotic Index><Modeling><Modern Man><Molecular><Molecular Biology><Molecular Carcinogenesis><Morbidity><Morbidity - disease rate><Multicultural Education><Multicultural Multilingual Education><Multicultural literacy><Multimodal Therapy><Multimodal Treatment><Mφ><National Cancer Burden><Nature><Non-Hodgkin's Lymphoma><Nonhodgkins Lymphoma><Obesity><Ohio><Oncogenic><Oncogenic Viruses><Outcome Study><PBMC><PD-L1><PDL-1><PDL1><Patients><Peer Review><Peripheral Blood Mononuclear Cell><Persons><Ph.D.><PhD><Pharmaceutical Preparations><Platelet Transforming Growth Factor><Policies><Population><Population Research><Population Sciences><Population-based research><Population-level research><Pre-Clinical Model><Preclinical Models><Prevention><Prognosis><Prognostic Factor><Prognostic/Survival Factor><Programmed Cell Death 1 Ligand 1><Programmed Death Ligand 1><Proliferation Index><Prostate><Prostate Gland><Prostatic Gland><Proteins><Public Health><Publications><Publishing><Regulatory T-Lymphocyte><Research><Resolution><Resource Sharing><Resource-constrained area><Resource-constrained community><Resource-constrained environment><Resource-constrained region><Resource-constrained setting><Resource-limited area><Resource-limited community><Resource-limited environment><Resource-limited region><Resource-limited setting><Resource-poor area><Resource-poor community><Resource-poor environment><Resource-poor region><Resource-poor setting><Reticulolymphosarcoma><Risk><Rural><S-Phase Fraction><Scanning><Scientific Publication><Scientist><Screening for cancer><Sight><Site><Solid Neoplasm><Solid Tumor><Strategic Planning><Sub-Saharan Africa><Subsaharan Africa><Systematics><TGF B><TGF-beta><TGF-β><TGFbeta><TGFβ><Technology><Therapeutic><Therapeutic Agents><Therapeutic Trials><Thyroid><Thyroid Gland><Thyroid Head and Neck><Tissue Growth><Tissues><Tobacco Consumption><Tobacco use><Training><Training and Outreach><Transforming Growth Factor beta><Transforming Growth Factor-Beta Family Gene><Translating><Translational Research><Translational Science><Treg><Tumor Burden><Tumor Load><Tumor Viruses><Tutoring and Outreach><Underserved Population><United States><Universities><University resources><Uterine Cervix Cancer><Virus-HIV><Vision><adiposity><angiogenesis><anti-cancer research><anticancer activity><attributable death><attributable mortality><biologic><blood cancer><cancer genetics><cancer microenvironment><cancer of blood><cancer of the blood><cancer prevention><cancer research><cancer research center director><causation><clinical development><cohort><colorectum><combination therapy><combined modality treatment><combined treatment><corpulence><death risk><developed country><developed nation><developed nations><developmental><disease causation><drug/agent><early cancer detection><ethnic minority><experience><experimental therapeutic agents><experimental therapeutics><flow cytophotometry><health care><herpes virus><high risk><immune evasive><immune microenvironment><immune-oncology><immuno oncology><immunology oncology><immunosuppressive microenvironment><immunosuppressive tumor microenvironment><improved outcome><in vivo><innovate><innovation><innovative><insight><interdisciplinary approach><interventional strategy><large cell Diffuse non-Hodgkin's lymphoma><leukemia><life span><lifespan><low and middle-income countries><malignancy><member><mortality><mortality risk><multi-modal therapy><multi-modal treatment><multidisciplinary approach><neoplasm/cancer><next generation><non-Hodgkins disease><novel><oncogenic tumor virus><oncoimmunology><ontogeny><outreach><patient navigation><pre-clinical><pre-clinical development><preclinical><preclinical development><programmed cell death ligand 1><programmed cell death protein ligand 1><programs><protein death-ligand 1><pulmonary><racial diversity><racial minority><racially diverse><recruit><regulatory T-cells><resolutions><response to therapy><response to treatment><scRNA-seq><screening><screening cancer patients><screenings><single cell RNA-seq><single cell RNAseq><single cell expression profiling><single cell transcriptomic profiling><single-cell RNA sequencing><survivorship><targeted agent><therapeutic response><therapeutically effective><therapy response><tobacco product use><transcriptomics><translation research><translational genomics><translational investigation><translational therapeutics><translational therapy><treatment response><treatment responsiveness><tumor><tumor immune microenvironment><tumor microenvironment><tumor-immune system interactions><under served group><under served individual><under served people><under served population><underserved group><underserved individual><underserved people><visual function>